A carregar...
Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma
PURPOSE: Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demo...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6188073/ https://ncbi.nlm.nih.gov/pubmed/30349306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173275 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|